Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation's Clinical Policies Committee
- May 1st, 2019
- Staff Publication
- Winikoff, B., Mark, A., Foster, M.A., Grossman, D., Prager, S.W., Reeves, M., Velásquez, C.V.
Contraception; Vol. 99(5):265-266; May 1, 2019; doi:https://doi.org/10.1016/j.contraception.2019.02.008
Early abortion continues to expand outside of traditional clinics, through telemedicine, self-managed medication abortion, or in smaller offices that do not specialize in obstetrical care. Consequently, requiring Rh testing and anti-D immunoglobulin as part of abortion care is becoming a barrier. As of early 2019, the Society of Family Planning , the American College of Obstetricians and Gynecologists , and the Society of Obstetricians and Gynecologists of Canada  recommend that all Rh D-negative women receive anti-D immunoglobulin after an induced abortion, regardless of gestational age or type of procedure.